title: Serum integrin-linked kinase (sILK) concentration and survival in non-small cell lung cancer: a pilot study.
abstract: BACKGROUND
  Integrin-linked kinase (ILK) is an intracellular signaling protein critically involved in cellular growth and motility. In non-small cell lung cancer (NSCLC), increased ILK expression has been associated with decreased recurrence-free and overall survival. Recently, ILK has also been detected in the serum of NSCLC patients.
  
  
  OBJECTIVE
  To assess the prognostic impact of preoperative serum ILK (sILK) concentration on overall survival in surgically amenable NSCLC.
  
  
  METHODS
  Preoperative sILK was quantified by ELISA in 50 newly diagnosed NSCLC patients. After surgery, patients were followed-up for a median interval of 2.5 years.
  
  
  RESULTS
  Serum ILK concentrations ranged from 0 to 2.44 ng/ml. Mean sILK was around 2.3 times higher in the 16 patients who died as compared to the 34 patients who survived (1.04 vs. 0.45 ng/ml, p = 0.001). In univariate time-to-event analysis, increased sILK was associated with adverse survival [Hazard ratio (HR): 4.03, 95 % CI: 2.00-8.13, p < 0.001]. This association prevailed after multivariable adjustment for several clinical, demographic, and laboratory parameters (HR: 3.85, 95 % CI: 1.53-9.72, p = 0.004).
  
  
  CONCLUSIONS
  Serum ILK shows potential as a novel strong and independent prognostic marker for postoperative survival in surgically amenable NSCLC.
authors: Division of Thoracic Surgery, Karl Landsteiner Institute for Thoracic Oncology, Otto Wagner Hospital, Sanatoriumstrasse 2, 1140, Vienna, Austria.
authors: F
authors: F
authors: Posch
authors: U
authors: U
authors: Setinek
authors: R M
authors: RM
authors: Flores
authors: D
authors: D
authors: Bernhard
authors: G E
authors: GE
authors: Hannigan
authors: M R
authors: MR
authors: Mueller
authors: S B
authors: SB
authors: Watzka
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000401:mortality*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D017346:Protein Serine-Threonine Kinases / Q000097:blood*; D015996:Survival Rate; D000099200:Scaffold Protein ILK
chemical_list: D017346:Protein Serine-Threonine Kinases; D000099200:Scaffold Protein ILK
references: J Thorac Cardiovasc Surg. 2011 Aug;142(2):384-9
references: 21620418
references: Nat Rev Immunol. 2002 Aug;2(8):569-79
references: 12154376
references: Am J Pathol. 2004 May;164(5):1807-15
references: 15111327
references: Eur J Cardiothorac Surg. 2013 May;43(5):940-5
references: 23045294
references: Nat Rev Cancer. 2005 Jan;5(1):51-63
references: 15630415
references: BMC Med. 2012 May 29;10:51
references: 22642691
references: Stata J. 2009 Jan 1;9(1):17-39
references: 20046933
references: Virchows Arch. 2003 Feb;442(2):118-23
references: 12596061
references: J Mol Histol. 2013 Apr;44(2):183-9
references: 23108908
references: Interact Cardiovasc Thorac Surg. 2008 Feb;7(1):107-10
references: 18048409
references: Clin Cancer Res. 2004 Apr 1;10(7):2415-20
references: 15073119
references: Eur J Cardiothorac Surg. 2011 Feb;39(2):180-4
references: 20580243
references: J Pathol. 2003 Oct;201(2):229-37
references: 14517840
references: Chest. 2002 Sep;122(3):1037-57
references: 12226051
references: J Cell Sci. 2008 Oct 1;121(Pt 19):3121-32
references: 18799788
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: BMC Cancer. 2005 Jan 05;5:1
references: 15631637
references: Eur J Cancer. 2005 Aug;41(12):1690-6
references: 16043346
references: Eur J Cardiothorac Surg. 2010 Sep;38(3):254-9
references: 20299233
references: BMJ. 2011 Apr 27;342:d2110
references: 21525094
references: Cell Cycle. 2009 Dec 15;8(24):4060-6
references: 19923885
references: Hum Pathol. 2007 Jul;38(7):1081-1091
references: 17442374